Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Vaginal ring for HIV prevention: a few details would have elevated good coverage to great

Analysis of BuzzFeed's coverage of vaginal ring studies.

Published
01 March 2016
From
Health News Review
Really Rapid Review — CROI 2016, Boston

Here is a carefully curated (I’m joking) list of highlights, a Really Rapid Review™ roughly divided into epidemiology/prevention, treatment, complications, cure — and coffee.

Published
01 March 2016
From
NEJM Journal Watch
Experimental TLR7 agonist suppresses HIV-like virus in monkeys after ART interruption

GS-9620, an investigational toll-like receptor or TLR7 agonist, led to immune activation in a study of macaque monkeys infected with an HIV-like virus, and two of the animals

Published
29 February 2016
By
Liz Highleyman
Life expectancy in HIV-positive people in the US still lags 13 years behind HIV-negative people

A study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) comparing life expectancies of HIV-positive and HIV-negative people within the Kaiser Permanente health insurance

Published
28 February 2016
By
Gus Cairns
European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), an investigational fixed-dose combination for the treatment of HIV-1 infection in adults and adolescents (ages 12 years and older with body weight at least 35 kg) in combination with other HIV antiretroviral agents.

Published
26 February 2016
From
Gilead press release
Immunotherapy agent can disrupt viral reservoir in SIV-infected monkeys

An immune-enhancing treatment can push SIV (simian immunodeficiency virus) out of its hideouts in infected monkeys that have the virus controlled with drugs, scientists at Yerkes National Primate Research Center, Emory University report.

Published
26 February 2016
From
Emory Health Sciences
Sangamo BioSciences Presents Phase 2 Immunological Data from SB-728-T ZFP Therapeutic® HIV Program at CROI 2016

Subjects from SB-728-1101 cohort 3* remain off antiretroviral therapy for over a year Immunologic and reservoir analyses suggest mechanism for viral load control.

Published
26 February 2016
From
Sangamo Biosciences press release
Dr. Robert Grant weighs in after the first case of failed PrEP: What does it mean?

At CROI today, researchers and providers heard a detailed case study of a man who was infected with drug-resistant HIV while taking PrEP. No study to date has definitively documented a “breakthrough” HIV infection during PrEP with adherence to Truvada, so the report has garnered a lot of attention and concern from community members. We spoke with Robert Grant, MD, MPH, to give context to the discussion about what this case means for people currently taking PrEP.

Published
26 February 2016
From
BETA blog
Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

A case report of a man in Toronto who became infected with a multi-drug-resistant strain of HIV despite apparently very consistent adherence to PrEP was presented at

Published
25 February 2016
By
Gus Cairns
Early antiretroviral therapy reduces the risk of infection-related cancers

People who started antiretroviral therapy at a CD4 cell count above 500 had a significantly lower risk of developing a cancer with an infectious cause when compared

Published
25 February 2016
By
Keith Alcorn

Filter by country